Further indicators of a pathogenic role of paranodal autoantibodies are the destruction of paranodal architecture detectable in patients with anti-CNTN1 associated neuropathy, the excellent therapeutic response to rituximab and the uniform clinical phenotype of the patients [4]. Here, CNTN1 is linked to neuropathy.